Abstract: Ingestible devices can directly deliver therapeutic agents to desired tissue(s) of the GI tract of a subject, such as the submucosa, the mucosa, and/or the mucus layer of the GI tract, and methods of using the same. The ingestible devices can deliver therapeutic agents in a safe, effective, and reliable manner. The disclosure also provides pharmaceutical compositions for use in methods of treating a disease or condition in a subject in need thereof.

Abstract: Ingestible devices can directly deliver therapeutic agents to desired tissue(s) of the GI tract of a subject, such as the submucosa, the mucosa, and/or the mucus layer of the GI tract, and methods of using the same. The ingestible devices can deliver therapeutic agents in a safe, effective, and reliable manner. The disclosure also provides pharmaceutical compositions for use in methods of treating a disease or condition in a subject in need thereof.

Abstract: This disclosure features methods and devices for treating diseases with orally-delivered biotherapeutics.

Abstract: Ingestible devices can directly deliver therapeutic agents to desired tissue(s) of the GI tract of a subject, such as the submucosa, the mucosa, and/or the mucus layer of the GI tract, and methods of using the same. The ingestible devices can deliver therapeutic agents in a safe, effective, and reliable manner. The disclosure also provides pharmaceutical compositions for use in methods of treating a disease or condition in a subject in need thereof.

Abstract: A method of treating a disease or condition in a subject in need thereof is disclosed. The method comprising: trans-epithelially administering a dispensable substance to the gastrointestinal (GI) tract of the subject by orally administering an ingestible device comprising the dispensable substance to the subject. The ingestible device is configured for trans-epithelial delivery of the dispensable substance to the GI tract of the subject and the dispensable substance comprises a pharmaceutical formulation comprising a therapeutically effective amount of a glucagon receptor agonist or a glucagon-like peptide-1 (GLP-1) receptor agonist. The ingestible device releases the dispensable substance as at least one jet to a desired location of the GI tract of the subject.

Abstract: This disclosure features methods and devices for treating diseases with orally-delivered biotherapeutics.

Abstract: Described is a method for screening an encoded chemical library, which library comprises a plurality of different chemical structures each releasably linked to an encoding tag, the method comprising the steps of: (a) providing said library of tagged chemical structures; (b) releasing each chemical structure from its tag to produce a plurality of free, tagless chemical structures (TCSs); (c) screening the TCSs by contacting them with a assay system under conditions whereby a spatial association between each TCS and its tag is maintained, to produce a plurality of different screened TCSs each spatially associated with its tag; and (d) identifying a screened TCS by decoding a tag that is spatially associated therewith.

Abstract: Disclosed is an encoded chemical library microbead, which microbead has immobilized thereon and/or therein: (i) an encoding tag; and (ii) a target assay system reporter moiety, wherein the reporter moiety exists in a first state in the absence of activity against the target and in a second state in the presence of said activity, and wherein said microbead further comprises a clonal population of one or more chemical structure(s) releasably linked thereto and encoded by said tag.

Abstract: An ingestible device, includes a storage reservoir configured to store a dispensable substance and a pressurized chamber configured so that, when a restraining force is removed from the pressurized chamber, the dispensable substance exits the ingestible device via openings in the ingestible device.

Abstract: A system for determining an emotional state of a subject includes a speech sensor for sensing a subject's speech, a receiving means arranged in communication with the speech sensor for receiving the sensed speech, a converting means for converting the sensed speech into text, a classifying means for classifying the text and speech characteristics of the subject's speech according to a predetermined set of human emotions, and an analysing means for analysing the classified text and speech characteristics so as to determine an emotional state of the subject. The classifying means is configured to compare sensed speech characteristics to characteristic references for allowing a user to determine a change in speech characteristics of the subject's speech relative the characteristic references during a conversation with the subject.

Abstract: An ingestible device, includes a storage reservoir configured to store a dispensable substance and a pressurized chamber configured so that, when a restraining force is removed from the pressurized chamber, the dispensable substance exits the ingestible device via openings in the ingestible device.

Abstract: MeCP2 based therapy. The present invention relates to synthetic polypeptides that are useful in the treatment of disorders associated with reduced MeCP2 activity, including Rett syndrome. The present invention provides synthetic polypeptides comprising: i) an MBD amino acid sequence showing at least 70% similarity with the amino acid sequence showing at least 70% similarity with the amino acid sequence as depicted in SEQ ID NO: 2, wherein the polypeptide has a deletion of at least 50 amino acids, when compared to the full length MeCP2 e1 and e2 sequences. The invention further provides nucleic acid constructs, expression vectors, virions, pharmaceutical compositions, and cells providing polynucleotides of the invention. The invention further provides methods of treating or preventing disease in an animal comprising administering to said animal a synthetic polypeptide according to the invention.

Abstract: Systems and techniques for generating and/or employing a computed tomography (CT) medical imaging intracranial hemorrhage model are presented. In one example, a system employs a convolutional neural network to generate classification output data regarding a brain anatomical region based on computed tomography (CT) data associated with the brain anatomical region. The system also detects presence or absence of a medical intracranial hemorrhage condition in the CT data based on the classification output data. Furthermore, the system determines a subtype of the medical intracranial hemorrhage condition based on the classification output data. The system also generates display data associated with the subtype of the medical intracranial hemorrhage condition in a human-interpretable format.

Abstract: An ingestible device, includes a storage reservoir configured to store a dispensable substance and a pressurized chamber configured so that, when a restraining force is removed from the pressurized chamber, the dispensable substance exits the ingestible device via openings in the ingestible device.

Abstract: There is provided a flavored vaporizable formulation comprising (i) one or more solvents; (ii) a flavor; and (iii) one or more cyclodextrins; wherein the flavored vaporizable formulation contains water in an amount of from 0 to 10 wt. % based on the vaporizable formulation.

Abstract: A patient interface that is comfortable for a user to wear is disclosed. The patient interface includes a forehead rest and cushion. In particular the cushion includes a deformable resilient member that when compressed creates a uniformly and gradually increasing force while evenly distributing the pressure on the forehead of the patient.

Abstract: A patient interface that is comfortable for a user to wear is disclosed. The patient interface includes a forehead rest and cushion. In particular the cushion includes a deformable resilient member that when compressed creates a uniformly and gradually increasing force while evenly distributing the pressure on the forehead of the patient.

Abstract: Disclosed herein is an apparatus for cooling a sterile liquid for use in cryotherapy, the apparatus comprising: a first chamber (202) adapted to receive a removable container (201) of sterile liquid and a fluid port for receiving a fluid for applying, in use, pressure to a received removable container (201); and a second chamber (203) comprising a cooler; wherein the first chamber (202) is arranged to be in thermal conductivity with the second chamber (203) such that, in use, the contents of the first chamber (202) are cooled by the cooler of the second chamber (203). Advantageously, embodiments provide a system, heat exchanger unit within the system and method for supplying a sterilised working fluid to a catheter system for cryotherapy, the working fluid being supplied at a desired and easily controllable temperature and flow rate.

Abstract: An aerosol preparation assembly includes an entrainment chamber defining an entrainment volume. The entrainment chamber includes a gas inlet port, an aerosol inlet port and an outlet port. The entrainment chamber is configured such that a velocity of a flow of a gas within the entrainment volume is less than a velocity of the flow of the gas within the gas inlet port. The entrainment chamber is configured such that at least a portion of inlet aerosol is entrained into the flow of the gas within the entrainment volume to produce an entrained aerosol flow at the outlet port. The particle selection chamber is configured to receive the entrained aerosol flow and produce an outlet aerosol flow. The particle selection chamber and nozzle are collectively configured such that a volumetric median diameter of the outlet aerosol flow is less than a volumetric median diameter of the inlet aerosol.

Abstract: The present invention provides nucleic acid molecules comprising a MeCP2 expression cassette, the expression cassette comprising, in operable linkage from 5? to 3?: a 5? transcriptional control region comprising a promoter capable of driving transcription in neural cells; an open reading frame encoding a MeCP2 protein; translation control signals; a 3? untranslated region (3?UTR) comprising one or more of: (i) a binding site for mir-22; (ii) a binding site for mir-19; (iii) a binding site for miR-132; (iv) a binding site for miR124; and (v) an AU-rich element; and transcriptional termination signals; wherein the MeCP2 expression cassette is not more than about 5 kb in length. The invention further provides viral vectors, especially vectors derived from adeno-associated virus (AAV), for use in therapeutic delivery of such expression cassettes.